The useof sodium-glucose cotransporter-2 inhibitors (SGLT2is) demonstrate favorableeffects in patients with and without type 2 diabetes (T2DM) in CVD especially forheart failure (HF), as the contemporary clinical practice recommendations andstandards of care advocate. Here, SLC5A2 is linked to type 2 diabetes mellitus.